inactivated hepatitis A vaccine

ApprovedVaccine

Boryung Pharmaceutical Co., Ltd

inactivated hepatitis A vaccine is one of 75 biologic programs targeting Hepatitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

Hepatitis BActive, not recruiting

COVID-19Active, not recruiting

HepatitisPhase 3

Active, not recruiting

Hepatitis BApproved

Active, not recruiting

COVID-19Approved

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

inactivated hepatitis A vaccine

Boryung Pharmaceutical Co., Ltd

Approved

1 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

SARS-COV-2 VACCINE

Moderna

Preclinical

2 5

Glucocorticoid

AbbVie

Preclinical

1 6

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 7

Interferon-Gamma

SSPP Pharmaclon Ltd.

Preclinical

1 8

MRNA COVID-19 Vaccine

Novartis

Preclinical

4 9

Exoflo

DDirect Biologics, LLC

Preclinical

3 10

Sivelestat Sodium

TThe First Hospital of Jilin University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatitis3 trials

Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine

Completed· Novartis logo

Novartis·Phase 3·NCT01453348·252 enrolled

To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A)

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 3·NCT03654677·253 enrolled

To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine

Completed· Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd·Phase 3·NCT03654664·119 enrolled

Immunogenicity2 trials

Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX

Completed·SSiriraj Hospital·Phase 4·NCT02526550·50 enrolled

Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV

Recruiting·—·Phase 3·NCT06978621·36 enrolled

Hepatitis B1 trial

Comparison of Immunization Schedules of Inactivated Hepatitis A Vaccine and Combined Hepatitis A and Hepatitis B Vaccine

Completed· Sinovac Biotech Co., Ltd logo

Sinovac Biotech Co., Ltd·Phase 4·NCT02445703·301 enrolled

COVID-191 trial

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine

Completed·SSinovac Research and Development Co., Ltd.·Phase 4·NCT04953325·270 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for inactivated hepatitis A vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — inactivated hepatitis A vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for inactivated hepatitis A vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boryung Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: Boryung Pharmaceutical Co., Ltd

inactivated hepatitis A vaccine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatitis3 trials

Immunogenicity2 trials

Hepatitis B1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News